“The clinical adoption of pharmacogenomics has been hampered by many obstacles and concerns. This article addresses many of them head on and proves that the scalable implementation of PGx can significantly reduce healthcare costs, improve outcomes and provide a better experience for patients and clinicians,” says the co- author Jeffrey A. Shaman, PhD, MS, Scientific Director at CLS.
The retrospective study analyzed the direct results of CLS’ pharmacogenomics-enriched Comprehensive Medication Management (PGx+CMM) program, unified by the CLS GeneDose LIVEMT clinical decision support system, out of 5,288 Medicare Advantage members (65 years and older) of January 2018 for August 2020. These individuals enrolled in the voluntary program through their health insurance plan with the Teachers’ Retirement System of the Kentucky State. The program is still ongoing and now has over 10,000 participants.
The system-wide implementation of PGx+CMM included member engagement, home saliva collection, and genetic testing to identify unique drug safety risks for each individual. Each patient analysis took into account the impact of an individual’s DNA on their response to medication, as well as many other traditional risk factors such as drug interactions, lifestyle factors (e.g. , food, alcohol, smoking) and age-related concerns. Using GeneDose LIVE, results were assessed by trained Know Your Rx Coalition pharmacists who consulted with each patient to create a medication action plan outlining any proposed changes. These recommendations were then passed on to the patient’s prescribing physician, who was responsible for implementing any medication changes.
The study results highlight the positive clinical and economic outcomes of the PGx + CMM program, including:
- Drug Safety Improvements
Studies have shown that almost everyone has variants in their DNA that impact medications and have been shown to be true in this population. 100% of participants had at least one variant known to impact drug therapy outcomes, and 66% of participants had genetic risks detected in a currently prescribed drug.
- A steady reduction in the use of healthcare resources
Among participants, inpatient visits decreased by 14.9%, emergency department visits decreased by 6.8% and outpatient visits decreased by 1.9%.
- Significant savings
Direct medical costs have been reduced by $218.34 per member per month for a cumulative savings of $37,027,769 more than 32 months. The savings were largely attributable to a decrease in emergency department visits and hospitalizations.
“One of the key lessons we observed was a positive shift in healthcare resource utilization from acute care services to more sustainable and cost-effective primary care options,” notes Dr. Shaman. “Through this program, patients, healthcare providers and the healthcare system as a whole have synergistically benefited. This evidence suggests that widespread adoption could significantly advance the goals of the Quadruple Aim in the global health systems.”
About Coriell Life Sciences
Coriell Life Sciences (CLS), a leader in genetic sciences, is spearheading innovation in precision medicine to reduce healthcare costs and foster a healthier world. Using advanced bioinformatics technology, CLS bridges the gap between genetic knowledge and clinical application and offers the most comprehensive drug risk management program on the market. Visit coriell.com, email [email protected] or follow @CoriellLife.
For Coriell Life Sciences
SOURCECoriell Life Sciences